A Randomized Trial Comparing Capizzi Escalating Methotrexate and High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma

What this Trial Is About

T-cell lymphoblastic lymphoma (T-LBL) is a common subtype of non-Hodgkin lymphoma affecting children and adolescents, with current treatments achieving event-free survival rates between 75% and 85%. This research compares two commonly used methotrexate intensification strategies—high dose methotrexate with leucovorin rescue (HD-MTX) and Capizzi-style methotrexate without leucovorin rescue plus pegylated asparaginase (C-MTX)—to evaluate which is more effective for newly diagnosed pediatric T-LBL patients. The study also explores the value of PET/CT imaging in pediatric T-LBL and considers treatment options for the small subgroup who do not achieve remission after initial induction therapy, including evaluating novel targeted therapies like dasatinib. Participants are divided into three groups based on their response to induction therapy and risk level. Standard risk patients who achieve at least a partial remission after induction receive either Capizzi escalating methotrexate or high dose methotrexate during interim maintenance, followed by delayed intensification and maintenance therapy, along with triple intrathecal injections. High risk patients who do not reach partial remission after induction undergo six intensive polychemotherapy blocks, delayed intensification, and maintenance therapy with triple intrathecal injections. Treatments include combinations of drugs such as prednisone, vincristine, pegylated-asparaginase, bortezomib, cytarabine, cyclophosphamide, daunorubicin, methotrexate, dexamethasone, and doxorubicin. Throughout the study, participants undergo assessments including PET/CT imaging and bone marrow minimal disseminated disease (MDD) measurements at diagnosis and during treatment to monitor outcomes. Researchers will measure event-free survival over four years, focusing on overall survival and response according to MDD levels. The study duration includes induction, consolidation, maintenance phases, and follow-up evaluations. Safety monitoring and response evaluations guide treatment adjustments, aiming to improve risk stratification and identify effective therapies for children and adolescents with T-LBL.

Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL)